233 related articles for article (PubMed ID: 33419089)
1. CHD4 Predicts Aggressiveness in PTC Patients and Promotes Cancer Stemness and EMT in PTC Cells.
Pratheeshkumar P; Siraj AK; Divya SP; Parvathareddy SK; Alobaisi K; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33419089
[TBL] [Abstract][Full Text] [Related]
2. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor.
Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D
J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537
[TBL] [Abstract][Full Text] [Related]
3. ALDH5A1 acts as a tumour promoter and has a prognostic impact in papillary thyroid carcinoma.
Deng XY; Gan XX; Feng JH; Cai WS; Wang XQ; Shen L; Luo HT; Chen Z; Guo M; Cao J; Shen F; Xu B
Cell Biochem Funct; 2021 Mar; 39(2):317-325. PubMed ID: 32881051
[TBL] [Abstract][Full Text] [Related]
4. Growth-associated protein 43 promotes thyroid cancer cell lines progression via epithelial-mesenchymal transition.
Zheng C; Quan RD; Wu CY; Hu J; Lin BY; Dong XB; Xia EJ; Bhandari A; Zhang XH; Wang OC
J Cell Mol Med; 2019 Dec; 23(12):7974-7984. PubMed ID: 31568662
[TBL] [Abstract][Full Text] [Related]
5. LncRNA CASC2 expression is down- regulated in papillary thyroid cancer and promotes cell invasion by affecting EMT pathway.
Zhou T; Zhong M; Zhang S; Wang Z; Xie R; Xiong C; Lv Y; Chen W; Yu J
Cancer Biomark; 2018; 23(2):185-191. PubMed ID: 30175973
[TBL] [Abstract][Full Text] [Related]
6. microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2492-2505. PubMed ID: 31565805
[TBL] [Abstract][Full Text] [Related]
7.
Wen J; Lin B; Lin L; Chen Y; Wang O
Aging (Albany NY); 2020 Aug; 12(16):16437-16456. PubMed ID: 32857728
[TBL] [Abstract][Full Text] [Related]
8. Defeating EpCAM(+) liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma.
Nio K; Yamashita T; Okada H; Kondo M; Hayashi T; Hara Y; Nomura Y; Zeng SS; Yoshida M; Hayashi T; Sunagozaka H; Oishi N; Honda M; Kaneko S
J Hepatol; 2015 Nov; 63(5):1164-72. PubMed ID: 26095183
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-1271 inhibits the progression of papillary thyroid carcinoma by targeting IRS1 and inactivating AKT pathway.
Chen Y; Hao SA; Jiang Y; Gao B; Tian WG; Zhang S; Guo LJ; Wang LL; Luo DL
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):7989-7999. PubMed ID: 31599424
[TBL] [Abstract][Full Text] [Related]
10. AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.
Ju G; Xing T; Xu M; Zhang X; Sun Y; Mu Z; Sun D; Miao S; Li L; Liang J; Lin Y
Neoplasia; 2024 Mar; 49():100972. PubMed ID: 38237535
[TBL] [Abstract][Full Text] [Related]
11. Silencing SIX1 inhibits epithelial mesenchymal transition through regulating TGF-β/Smad2/3 signaling pathway in papillary thyroid carcinoma.
Min WP; Wei XF
Auris Nasus Larynx; 2021 Jun; 48(3):487-495. PubMed ID: 33077306
[TBL] [Abstract][Full Text] [Related]
12. Linc00941 Is a Novel Transforming Growth Factor β Target That Primes Papillary Thyroid Cancer Metastatic Behavior by Regulating the Expression of Cadherin 6.
Gugnoni M; Manicardi V; Torricelli F; Sauta E; Bellazzi R; Manzotti G; Vitale E; de Biase D; Piana S; Ciarrocchi A
Thyroid; 2021 Feb; 31(2):247-263. PubMed ID: 32495722
[No Abstract] [Full Text] [Related]
13. CHD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.
Luo CW; Wu CC; Chang SJ; Chang TM; Chen TY; Chai CY; Chang CL; Hou MF; Pan MR
Exp Cell Res; 2018 Feb; 363(1):65-72. PubMed ID: 29305962
[TBL] [Abstract][Full Text] [Related]
14. CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma.
Shao S; Cao H; Wang Z; Zhou D; Wu C; Wang S; Xia D; Zhang D
Clin Epigenetics; 2020 Feb; 12(1):31. PubMed ID: 32070428
[TBL] [Abstract][Full Text] [Related]
15. Eva-1 homolog A promotes papillary thyroid cancer progression and epithelial-mesenchymal transition via the Hippo signalling pathway.
Lin BY; Wen JL; Zheng C; Lin LZ; Chen CZ; Qu JM
J Cell Mol Med; 2020 Nov; 24(22):13070-13080. PubMed ID: 32969138
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of RET gene mediated EGFR signaling pathway on epithelial-mesenchymal transition, proliferation and apoptosis of papillary thyroid carcinoma cells.
Zhao YL; Yuan BQ; Shen GS
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8036-8047. PubMed ID: 32767330
[TBL] [Abstract][Full Text] [Related]
17. ABCG2/BCRP gene expression is related to epithelial-mesenchymal transition inducer genes in a papillary thyroid carcinoma cell line (TPC-1).
Mato E; González C; Moral A; Pérez JI; Bell O; Lerma E; de Leiva A
J Mol Endocrinol; 2014 Jun; 52(3):289-300. PubMed ID: 24643400
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of long noncoding RNA SLC26A4-AS1 inhibits the epithelial-mesenchymal transition via the MAPK pathway in papillary thyroid carcinoma.
Wang DP; Tang XZ; Liang QK; Zeng XJ; Yang JB; Xu J
J Cell Physiol; 2020 Mar; 235(3):2403-2413. PubMed ID: 31556116
[TBL] [Abstract][Full Text] [Related]
19. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK/ERK and PI3K/AKT pathways.
Yu ST; Zhong Q; Chen RH; Han P; Li SB; Zhang H; Yuan L; Xia TL; Zeng MS; Huang XM
Cell Death Dis; 2018 Mar; 9(3):371. PubMed ID: 29515111
[TBL] [Abstract][Full Text] [Related]
20. IL13RA2 Is Differentially Regulated in Papillary Thyroid Carcinoma vs Follicular Thyroid Carcinoma.
Chong ST; Tan KM; Kok CYL; Guan SP; Lai SH; Lim C; Hu J; Sturgis C; Eng C; Lam PYP; Ngeow J
J Clin Endocrinol Metab; 2019 Nov; 104(11):5573-5584. PubMed ID: 31290966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
